# Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals reports Q4 and Full Year [----] financial results, with recent social posts highlighting analyst target price adjustments and earnings discussions.

### About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics.  
Alnylam Pharmaceuticals, Inc. uses the ticker $ALNY for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Alnylam Pharmaceuticals, Inc. (ALNY) social dominance is up 754.72% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) creators is up 34.48% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) engagements is up 254.2% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) mentions is up 63.79% from the previous week.
- Alnylam Pharmaceuticals, Inc. (ALNY) posts created is up 157.14% from the previous week.

### Price: $314.40
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/close.tsv)  
The stock price is experiencing volatility, with positive clinical trial data and strong sales being offset by regulatory concerns and negative social media sentiment, leading to a balanced outlook.  

24-Hour: 1.92%
7-Day: -4.99%
30-Day: -12.49%

1-Year High: $491.20 on 2025-10-20  
1-Year Low: $224.30 on 2025-04-08  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/alt_rank.tsv)  
Alnylam Pharmaceuticals, Inc. (ALNY) is currently AltRank #806 based on combined combined social and market metrics
Daily Average: [---]  
[--] Week: [---] [----]  
[--] Month: [---] +17  
[--] Months: [---] +114  
[--] Year: [---] [----]  
1-Year High: [-----] on 2025-06-08  
1-Year Low: [--] on 2025-03-22  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] no change  
[--] Month: [--] +15  
[--] Months: [--] [---]  
[--] Year: [--] +2  
1-Year High: [--] on 2026-01-01  
1-Year Low: [--] on 2025-06-26  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [------]  
[--] Week: [-------] +254%  
[--] Month: [-------] -39%  
[--] Months: [---------] -24%  
[--] Year: [---------] -22%  
1-Year High: [-------] on 2025-03-21  
1-Year Low: [-----] on 2026-02-01  

Engagements by network (24h):
Reddit: [--]
News: [---]
X: [------]
YouTube: [--]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [---]  
[--] Week: [---] +64%  
[--] Month: [---] +3%  
[--] Months: [-----] -30%  
[--] Year: [-----] -15%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-12-07  

Mentions by network (24h):
Reddit: [--]
News: [--]
X: [---]
YouTube: [--]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning Alnylam Pharmaceuticals, Inc. (ALNY) in the last [--] hours which is up 34% from [--] in the previous [--] hours
Daily Average: [---]  
[--] Week: [---] +34%  
[--] Month: [---] +6.60%  
[--] Months: [-----] -40%  
[--] Year: [-----] +54%  
1-Year High: [---] on 2025-06-29  
1-Year Low: [--] on 2025-12-07  

The most influential creators that mention Alnylam Pharmaceuticals, Inc. in the last [--] hours

| Creator                                            | Rank | Followers | Posts | Engagements |
| -------                                            | ---- | --------- | ----- | ----------- |
| [@earnings_guy](/creator/twitter/earnings_guy)     | [--]    | [------]    | [--]     | [-----]       |
| [@GeneInvesting](/creator/twitter/GeneInvesting)   | [--]    | [------]    | [--]     | [-----]       |
| [@RNAiAnalyst](/creator/twitter/RNAiAnalyst)       | [--]    | [------]    | [--]    | [-----]       |
| [@stocket_rocket](/creator/twitter/stocket_rocket) | [--]    | [--]        | [--]     | [-----]       |
| [@somoscdi](/creator/twitter/somoscdi)             | [--]    | [------]    | [--]     | [---]         |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA)   | [--]    | [-----]     | [--]     | [---]         |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)         | [--]    | [-----]     | [--]     | [---]         |
| [@Tickeron](/creator/twitter/Tickeron)             | [--]    | [------]    | [--]     | [---]         |
| [@doepke_michel](/creator/twitter/doepke_michel)   | [--]    | [-----]     | [--]     | [---]         |
| [@OzmosiHealth](/creator/twitter/OzmosiHealth)     | [--]   | [-----]     | [--]     | [---]         |

[View More](/list/creators/alnylam-pharmaceuticals-inc/100)
  
  
### Sentiment: 60%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/sentiment.tsv)  
Current Value: 60%  
Daily Average: 67%  
[--] Week: 75% +4%  
[--] Month: 65% +13%  
[--] Months: 65% -25%  
[--] Year: 65% +5%  
1-Year High: 100% on 2025-07-29  
1-Year Low: 26% on 2025-12-02  

Most Supportive Themes:
- Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase [--] study shows reduced gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its use as a first-line therapy.
- Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and increased its [----] revenue guidance, indicating positive financial performance.
- First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient has been dosed in the ZENITH Global Phase [--] cardiovascular outcomes trial of Zilebesiran, marking progress in its clinical pipeline.
  
Most Critical Themes:
- Negative Sentiment on X: (20%) A significant portion of posts on X express negative sentiment, with users raising concerns about the company.
- FDA Crackdown and Ad Pull: (10%) Alnylam has withdrawn TV advertisements following regulatory action on drug industry advertising, which may lead to concerns.
  
  
  
### Social Dominance: 0.016%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/social_dominance.tsv)  
Current Value: 0.016%  
Daily Average: 0.025%  
[--] Week: 0.045% +0.04%  
[--] Month: 0.025% -0.0008000000000000021%  
[--] Months: 0.025% -0.012%  
[--] Year: 0.025% -0.014%  
1-Year High: 0.065% on 2025-03-24  
1-Year Low: 0.0055% on 2025-12-07  
  
  
### Market Dominance: 0.047%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/market_dominance.tsv)  
Current Value: 0.047%  
Daily Average: 1%  
1-Year High: 2.10% on 2025-12-02  
1-Year Low: 0.047% on 2026-02-14  
  
  
### Market Cap: $41,536,584,379
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:alnylam-pharmaceuticals-inc/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/market_cap.tsv)  
Current Value: $41,536,584,379  
Daily Average: $47,051,828,190  
[--] Week: $41,696,716,474 -2.60%  
[--] Month: $41,696,716,474 -12%  
[--] Months: $41,696,716,474 -30%  
[--] Year: $41,696,716,474 +26%  
1-Year High: $64,388,633,748 on 2025-10-20  
1-Year Low: $29,032,966,164 on 2025-04-08  

### Top Alnylam Pharmaceuticals, Inc. News
Top news links shared on social in the last [--] hours  

*Showing a maximum of [--] news posts without a LunarCrush subscription.*  

"Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year [----] Financial Results and Highlights Recent Period Progress CAMBRIDGE Mass. February [--] 2026--Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company today reported its consolidated financial results for the fourth quarter and full year ended December [--] [----] and reviewed recent business highlights"  
[News Link](https://finance.yahoo.com/news/alnylam-pharmaceuticals-reports-fourth-quarter-130000068.html) [@YahooFinance](/creator/x/YahooFinance) 2026-02-12T13:15Z 2M followers, [----] engagements



### Top Alnylam Pharmaceuticals, Inc. Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"Nex-Z $NTLA vs. $ALNY Pros: best data weve ever seen across the board on ALL metrics one and done in 2-4 hour outpatient drip no concern for yearly insurance no variability Cons: rare liver elevations in elderly patients (especially in CM) must be mitigated and lowered as much as possible. RNAi seen as safer with longer track record overall and reversible Nucresiran Pros: could be even higher % KD only 2x per year instead of 4x (Amvuttra/Vutrisiran) reversible Cons: only seen KD data from healthy volunteers 2x per year instead of [--] and done need insurance reauthorizations some worry knocking"  
[X Link](https://x.com/GeneInvesting/status/2022438849520308302) [@GeneInvesting](/creator/x/GeneInvesting) 2026-02-13T22:32Z 15.3K followers, [----] engagements


"Because food is poisoned. Top proteinrelated stocks to watch: $BYND $ABUS $ADM $ALDX $ALNY $ANIX $APRE $ARTL $ARVN $DAR $ORMP"  
[X Link](https://x.com/safehavenmoney/status/2022385509901963347) [@safehavenmoney](/creator/x/safehavenmoney) 2026-02-13T19:00Z 44.1K followers, [---] engagements


"$ALM -B. Riley raises Almonty Industries target to $17 from $10 Buy - $ALNY -Chardan Capital lowers Alnylam Pharmaceuticals target to $425 from $475 Buy - $AM -Wells Fargo raises Antero Midstream target to $21 from $20 = Weight -"  
[X Link](https://x.com/MarcJacksonLA/status/2022375803288428859) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2026-02-13T18:22Z [----] followers, [---] engagements


"Earnings roundup: Neurocrine slumps Alnylam battles skeptics and Ascendis eyes a competitor $NBIX $ALNY $ASND by @realJacobBell https://www.biopharmadive.com/news/alnylam-neurocrine-ascendis-biotech-earnings-4q-2025/812137/ https://www.biopharmadive.com/news/alnylam-neurocrine-ascendis-biotech-earnings-4q-2025/812137/"  
[X Link](https://x.com/BioPharmaDive/status/2022360018042130840) [@BioPharmaDive](/creator/x/BioPharmaDive) 2026-02-13T17:19Z 13.7K followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing